DelveInsight’s, “DNA Topoisomerase I Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA Topoisomerase I Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DNA Topoisomerase I Inhibitors: Overview
DNA topoisomerases regulate the number of topological links between two DNA strands (i.e. change the number of superhelical turns) by catalysing transient single- or double-strand breaks, crossing the strands through one another, then resealing the breaks. Type I topoisomerases are ATP-independent enzymes (except for reverse gyrase), and can be subdivided according to their structure and reaction mechanisms: type IA (Topo IA; bacterial and archaeal topoisomerase I, topoisomerase III and reverse gyrase) and type IB (Topo IB; eukaryotic topoisomerase I and topoisomerase V). These enzymes are primarily responsible for relaxing positively and/or negatively supercoiled DNA, except for reverse gyrase, which can introduce positive supercoils into DNA. This function is vital for the processes of replication, transcription, and recombination.
The companies and academics are working to assess challenges and seek opportunities that could influence DNA Topoisomerase I Inhibitors R&D. The therapies under development are focused on novel approaches for DNA Topoisomerase I Inhibitors.
This segment of the DNA Topoisomerase I Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA Topoisomerase I Inhibitors Emerging Drugs
Sacituzumab govitecan: Immunomedics
Sacituzumab govitecan is an antibody–drug conjugate composed of an antitrophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa antibody coupled to SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor through a proprietary hydrolyzable linker. Currently, it is in Phase III stage of development to treat Solid tumours.
Trastuzumab Deruxtecan: Daiichi Sankyo
Trastuzumab deruxtecan is a HER2 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Trastuzumab deruxtecan (5.4 mg/kg) is approved in the U.S. and Japan for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. Trastuzumab deruxtecan (6.4 mg/kg) is also approved in Japan for the treatment of patients with HER2 positive unresectable advanced or recurrent gastric cancer.
Further product details are provided in the report……..
This segment of the report provides insights about the different DNA Topoisomerase I Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the DNA Topoisomerase I Inhibitors. The companies which have their DNA Topoisomerase I Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Immunomedics.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
DNA Topoisomerase I Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA Topoisomerase I Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA Topoisomerase I Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
DNA Topoisomerase I Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
DNA Topoisomerase I Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Sacituzumab govitecan: Immunomedics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Irinotecan hydrochloride liposomal: Luye Pharma Group
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Irinotecan: Valent Technologies
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
DNA Topoisomerase I Inhibitors Key Companies
DNA Topoisomerase I Inhibitors Key Products
DNA Topoisomerase I Inhibitors- Unmet Needs
DNA Topoisomerase I Inhibitors- Market Drivers and Barriers
DNA Topoisomerase I Inhibitors- Future Perspectives and Conclusion
DNA Topoisomerase I Inhibitors Analyst Views
DNA Topoisomerase I Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for DNA Topoisomerase I Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for DNA Topoisomerase I Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Immunomedics
• Daiichi Sankyo
• Ipsen
• Luye Pharma Group
• Hanmi Pharmaceutical
• Biocompatibles International
• Valent Technologies
• Elucida Oncology
• Cybrexa Therapeutics
• Linus Oncology
• Lee's Pharmaceutical
• SN BioScience
• Cebiotex
